Scanner

BIOTECH CATALYST AI SCANNER — March WK3

Biotech just gave back three weeks of gains in a single session. XBI dropped to $122.62 — virtually unchanged from where it started the year — after a broad risk-off move that hit small-caps harder than large-cap pharma. The catalyst? Rising yields, tariff escalation noise, and a general loss of patience with anything that doesn't generate revenue today. For catalyst traders, that's the setup: sentiment is washing out, but the calendar doesn't care about macro.

This week's scanner is loaded with imminent readouts. Three Phase 3 topline events (KPTI, ALMS, KOD), two PDUFA decisions (RCKT, GRCE), and a cluster of Phase 2 data drops — all within the next 6 weeks. The scoring spread is wider than recent weeks, with BSI ranging from 5.5 to 7.0 in the featured picks, meaning the scanner is genuinely differentiating between strong setups and marginal ones rather than handing everyone an 8.

What We're Tracking:

Trading Below Cash: BCYC ($519M cash vs. $350M cap)
Cash Pressure: OCGN, PCSA, OSTX, MBRX, ALZN
Initial Data: KPTI, ALMS, KOD, NVCR, MBRX, INSM, IDYA
Multi-Catalyst: KYTX (MG + SPS data at AAN in April)
Oversold: KPTI (RSI 28.8), INSM (RSI 20.5)

Featured Catalysts

#1. KPTI — Karyopharm Therapeutics Inc.

THE CATALYST
Event: Selinexor (SENTRY) — Phase 3 Topline Data in JAKi-naive myelofibrosis
Date: Q1 2026 (Est.)
FDA Status: Fast Track Designation
BSI: 8.02/10

Selinexor traps tumor suppressors inside cancer cell nuclei by blocking XPO1 — a first-in-class mechanism. Combined with ruxolitinib, it attacks myelofibrosis from a completely different angle than standard JAK inhibitors.

The Setup: Selinexor is the only XPO1 inhibitor in Phase 3 for myelofibrosis — a space where ruxolitinib monotherapy hits SVR35 in just 33% of patients and newer JAK inhibitors like momelotinib and fedratinib haven't cracked the combination code. SENTRY enrolled 353 patients in a 2:1 randomized design, the first real test of this approach in JAKi-naive disease. Oversold at RSI 28.8 heading into data.

Science & Edge: Selinexor inhibits XPO1, restoring nuclear retention of tumor suppressors like p53 that JAK inhibitors don't touch. SENTRY's co-primary endpoints — SVR35 at week 24 and symptom score reduction — are designed for superiority over ruxolitinib monotherapy. Phase 2 XPORT-MF-035 showed activity in both endpoints. The oral formulation adds to existing Xpovio infrastructure already commercializing in multiple myeloma.

The Edge: No other combination has beaten ruxolitinib monotherapy in a randomized Phase 3. Pelabresib came closest with positive data in November 2024, but targets a different patient population (add-on, not frontline combo). SENTRY's 353-patient frontline design is the highest-powered bet in the space.
The Risk: Karyopharm has 14 months of cash. A positive readout still leaves commercialization funding unresolved — the company would likely need a partner or raise before launch. A miss here essentially ends the myelofibrosis thesis; the existing Xpovio franchise isn't growing fast enough to sustain the company alone.

#2. ALMS — Alumis Inc.

THE CATALYST
Event: ESK-001 (ONWARD3) — Phase 3 Topline Data in moderate-to-severe plaque psoriasis
Date: Q1 2026 (Est.)
BSI: 7.90/10

ESK-001 is an oral allosteric TYK2 inhibitor that targets inflammatory signaling in psoriasis with high selectivity, avoiding the broad immunosuppression associated with older JAK inhibitors.

The Setup: Bristol-Myers' deucravacitinib proved oral TYK2 works in psoriasis but left room for improvement — PASI 75 rates were good, not great. Alumis is betting ESK-001 can close the gap with IL-23 biologics like risankizumab while keeping the oral convenience advantage. Phase 2 OLE showed most patients on 40mg BID hitting PASI 75 at 28 weeks, but Phase 3 is a different bar. The stock has drifted down 2% into the readout at a quiet RSI of 37 — the market isn't pricing in a blowout.

Science & Edge: ESK-001 is a highly selective allosteric TYK2 inhibitor blocking IL-12/IL-23 signaling. Phase 2 OLE data at EADV 2024 showed PASI 75 at 28 weeks in most patients on 40mg BID, with a clean safety profile. The allosteric binding site avoids the catalytic domain targeted by first-gen JAK inhibitors, which is why deucravacitinib got the FDA's black box warning waiver — a major commercial advantage for the TYK2 class.

The Edge: Oral convenience in a market dominated by injectables. Risankizumab and guselkumab set a high bar, but patients and payers want pills. If ESK-001 matches deucravacitinib's safety and beats its efficacy, the oral TYK2 space doubles in size. Japan licensing deal already secured provides non-dilutive capital.
The Risk: Psoriasis is a solved problem for many patients — IL-23 biologics hit PASI 90 in 60%+ of patients. ESK-001 needs to be close to that bar, not just better than deucravacitinib. Phase 3 miss on PASI 75 co-primary versus placebo is unlikely, but the market will judge ESK-001 against biologic benchmarks, not placebo.

#3. RCKT — Rocket Pharmaceuticals Inc.

THE CATALYST
Event: KRESLADI (marnetegragene autotemcel) — PDUFA Regulatory Decision for LAD-I
Date: Mar 28, 2026
BSI: 7.88/10

KRESLADI is a gene therapy that inserts a functional CD18 gene into a patient's own stem cells to correct Leukocyte Adhesion Deficiency-I, a rare pediatric immune disorder with no approved treatment and over 50% mortality by age two.

The Setup: Rocket already got rejected once — a CRL in June 2024 citing manufacturing concerns. The stock has ripped 52% in three weeks on the resubmission acceptance, pricing in a different outcome this time. If KRESLADI clears on March 28, it becomes the first gene therapy for LAD-I, an ultra-rare condition where the only current option is bone marrow transplant with its own significant mortality. Pivotal data is strong: 9/9 engraftment, 7/9 transfusion independence at 3.5+ years of follow-up.

Science & Edge: KRESLADI uses ex vivo lentiviral transduction of autologous HSCs to express functional ITGB2 (CD18), restoring neutrophil adhesion and extravasation. Pivotal results showed 100% engraftment and 78% transfusion independence with median 3.5+ year follow-up. The approach mirrors validated platforms — Zynteglo and Strimvelis use similar lentiviral correction of monogenic diseases — but targets an indication with zero competition.

The Edge: No competition. Zero approved therapies for LAD-I. The pivotal data is as clean as it gets for a gene therapy — 100% engraftment in every patient treated. If the manufacturing fixes satisfy FDA, the approval pathway is unobstructed. RMAT designation and orphan status stack the incentives.
The Risk: FDA already said no once. The CRL was about manufacturing, not efficacy — but CMC issues can be stubborn, and a second rejection would be devastating for a company whose entire near-term thesis hangs on this one decision. The 52% run into the PDUFA means the downside on a second CRL is severe.

#4. KOD — Kodiak Sciences Inc.

THE CATALYST
Event: Tarcocimab tedromer (GLOW2) — Phase 3 Topline Data in non-proliferative diabetic retinopathy
Date: Q1 2026 (Est.)
BSI: 7.72/10

Tarcocimab is an anti-VEGF therapy designed to last longer in the eye, using a biopolymer conjugate that extends drug half-life in retinal tissue — potentially cutting injection frequency from monthly to quarterly.

The Setup: Kodiak's story is a redemption arc. Earlier Phase 3 results were mixed, forcing a formulation redesign. Now GLOW2 arrives with a modified biopolymer and the question everyone in retina is asking: can tarcocimab actually deliver the durability advantage that justified a $1.4B valuation? The competitive field has gotten crowded since Kodiak started — axpaxli showed 89% injection burden reduction, vorolanib's LUCIA trial reported 73%, and CLS-AX hit 84%. Tarcocimab needs to be in that range or better.

Science & Edge: Tarcocimab conjugates an anti-VEGF antibody to a biopolymer, splitting into immediate-acting and slow-release components. November 2023 AAO data showed the primary endpoint was met with superiority in 2-step DRSS improvement. The modified formulation reduces biopolymer content to address prior tolerability signals while preserving the durability mechanism.

The Edge: Tarcocimab already demonstrated superiority on the primary DRSS endpoint at AAO 2023. The NPDR indication is strategic — it treats disease before it progresses to the injection-heavy proliferative stage, which could capture patients earlier than competitors focused on wet AMD or DME.
The Risk: Three competing long-acting therapies are advancing through Phase 3 with comparable burden-reduction claims. Tarcocimab's formulation modification introduces a variable — the modified version hasn't been tested at this scale before. If durability data doesn't clearly separate from axpaxli or vorolanib, the market won't reward incremental improvement at this valuation.

#5. NBP — NovaBridge Biosciences

(formerly IMAB)

THE CATALYST
Event: Givastomig (CLDN18.2 x 4-1BB bispecific) — Phase 1b Full Results in HER2-negative metastatic gastric cancer
Date: Q1 2026 (Est.)
FDA Status: Orphan Drug Designation
BSI: 7.46/10

Givastomig is a bispecific antibody that bridges CLDN18.2 on tumor cells with 4-1BB on T cells, activating the immune system directly at the tumor site while avoiding the liver toxicity that sank earlier 4-1BB agonists.

The Setup: The gastric cancer immunotherapy space has a new benchmark: zolbetuximab (Astellas) proved CLDN18.2 targeting works, but as a naked antibody it leaves efficacy on the table. Givastomig's Phase 1b combo data — 77% ORR, 16.9-month median PFS — blew past standard immunochemotherapy benchmarks of ~50% ORR and 7-8 month PFS. The stock has pulled back 13% despite this data, and Phase 2 enrollment started ahead of schedule in February. Detailed Phase 1b results at a major conference in H2 2026 will be the next valuation catalyst.

Science & Edge: Givastomig bispecifically targets CLDN18.2 and 4-1BB for proximal T-cell activation in the tumor microenvironment. Phase 1b data with nivolumab and mFOLFOX6 showed 77% ORR at 8 mg/kg and 73% at 12 mg/kg, with 16.9-month median PFS and 82% 6-month PFS in first-line HER2-negative gastric cancer. Efficacy held across CLDN18.2 and PD-L1 expression levels — an important differentiator from biomarker-restricted competitors.

The Edge: 77% ORR and 16.9-month PFS in first-line gastric cancer is best-in-class data. Zolbetuximab, the only approved CLDN18.2 therapy, showed more modest efficacy without T-cell costimulation. Givastomig's tumor-conditional 4-1BB activation avoids the hepatotoxicity that killed systemic 4-1BB agonists from Pfizer and BMS.
The Risk: This is Phase 1b data in a small patient cohort — the 180-patient Phase 2 pivotal won't read out until 2027. A lot can change between 77% ORR in a handful of patients and a registration-quality dataset. The ex-China rights structure complicates partnership dynamics and commercialization planning.

#6. GRCE — Grace Therapeutics Inc.

THE CATALYST
Event: GTX-104 (STRIVE-ON) — PDUFA Regulatory Decision for subarachnoid hemorrhage
Date: Apr 23, 2026
FDA Status: Orphan Drug Designation
BSI: 7.46/10

GTX-104 reformulates nimodipine — the standard of care for brain aneurysm bleeding — into an IV-injectable nanoparticle suspension, eliminating the messy and error-prone nasogastric tube administration currently required in ICU patients.

The Setup: Every neurosurgeon knows the problem: nimodipine capsules have to be drawn into a syringe, squirted down an NG tube, and prayed to absorb consistently in an unconscious patient. Tube clogs, dosing errors, and variable pharmacokinetics are the norm. No one has solved this in decades because the market is small (~30,000 SAH patients/year in the US) and the patent landscape was unappealing. Grace went after it anyway. STRIVE-ON showed a 19% reduction in clinically significant hypotension versus oral. Orphan designation locks in seven years of exclusivity if approved.

Science & Edge: GTX-104 uses nanoparticle technology for direct peripheral IV infusion of nimodipine, bypassing the gastrointestinal absorption variability of oral administration. Phase 3 STRIVE-ON demonstrated a 19% reduction in clinically significant hypotension versus oral nimodipine, with lower PK variability. Over 200 patients treated with favorable tolerability.

The Edge: First-mover in a space with zero competition. No other company has an IV nimodipine formulation in development. The captive hospital ICU market means no DTC marketing spend — sales teams call on a defined universe of neurointensive care units. Orphan exclusivity blocks generics for seven years.
The Risk: SAH affects ~30,000 US patients per year. Even with orphan pricing, the revenue ceiling is real. Grace is a single-asset company — if the PDUFA goes sideways, there's no pipeline to fall back on. Hospital formulary adoption is notoriously slow, and the company has never launched a product.

#7. OCGN — Ocugen, Inc.

THE CATALYST
Event: OCU410 (ArMaDa) — Phase 2 Full Results in geographic atrophy
Date: Q1 2026 (Est.)
BSI: 7.44/10

OCU410 delivers the RORA gene via a single subretinal AAV5 injection to treat geographic atrophy in dry AMD, targeting lipid metabolism, oxidative stress, and inflammation simultaneously — unlike approved complement inhibitors that address only one pathway.

The Setup: Syfovre and Izervay proved the GA market is real but left patients wanting — both require repeated injections and slow lesion growth by only 14-30%. OCU410's Phase 2 ArMaDa data already showed 46% lesion reduction (p=0.015) with the medium dose hitting 54%. That's a genuine step-change. But the stock has run 66% into this data release and sits overbought at RSI 72, while the balance sheet tells a different story: six months of cash and no revenue. The full Phase 2 readout has to be convincing enough to attract a partner or finance Phase 3.

Science & Edge: OCU410 modulates RORA to address GA through multiple mechanisms — lipid metabolism, oxidative stress, and inflammation — rather than the single complement pathway targeted by Syfovre (C3) and Izervay (C5). Phase 2 showed 46% lesion growth reduction versus control (p=0.015), 54% in the medium-dose cohort, and 60% slower ellipsoid zone loss in Phase 1. No serious adverse events. One-time dosing versus chronic monthly/bimonthly injections is the core commercial pitch.

The Edge: Only gene therapy in GA showing both structural preservation and functional signals. Syfovre and Izervay slow progression by 14-30% with repeated injections and carry wet AMD conversion risk. A one-time subretinal dose with 46-54% reduction and photoreceptor preservation data would redefine the treatment paradigm for a $5B+ market.
The Risk: Six months of cash. Full stop. Ocugen has never manufactured gene therapy at scale, and Phase 3 initiation in 2026 requires money they don't have. Even stellar data leads to a financing event before it leads to an approval. The 66% momentum run prices in good news — disappointment from here has a long way to fall.

#8. PCSA — Processa Pharmaceuticals Inc.

THE CATALYST
Event: NGC-Capecitabine (PCS6422) — Phase 2 Interim Data in breast cancer
Date: Q1 2026 (Est.)
BSI: 7.29/10

PCS6422 inhibits DPD (dihydropyrimidine dehydrogenase) to boost the cancer-killing metabolite of capecitabine by 2-10x, improving chemotherapy efficacy in breast cancer without the added toxicity of dose escalation.

The Setup: Negative cash balance. Micro float at 2.3M shares. Phase 2 interim data imminent. This is as binary as biotech gets. Processa is trying to improve a generic chemotherapy backbone — capecitabine — by fixing its metabolism problem. December 2025 data showed increased metabolite exposure with safety comparable to capecitabine alone, which is promising but preliminary. The question is whether the interim readout shows enough clinical signal to attract a licensing partner before the company runs out of oxygen entirely.

Science & Edge: PCS6422 inhibits DPD, the enzyme that degrades 5-FU before it can kill cancer cells. This boosts active metabolite exposure 2-10x from standard capecitabine without adding toxicity. Phase 2 data confirmed the PK uplift in December 2025. The mechanism is rationally designed and biologically straightforward — DPD variability is a known problem in fluoropyrimidine chemotherapy that affects 3-5% of patients severely and limits efficacy in many more.

The Edge: PCS6422 solves a known pharmacology problem in one of the most widely prescribed chemotherapies in oncology. If interim efficacy data confirms the PK advantage translates to clinical benefit, the compound becomes relevant across multiple tumor types — not just breast cancer. Low market cap on a micro float means even modest positive news moves the stock substantially.
The Risk: The company has negative cash. Not low cash — negative. Clinical operations at this funding level depend entirely on existing cash commitments and receivables. Any delay in data or partnership discussions risks operational shutdown. The breast cancer interim is an early read on a small trial — this isn't registrational data, and the market for improved capecitabine faces generic headwinds.

#9. NVCR — NovoCure Limited

THE CATALYST
Event: Tumor Treating Fields (PANOVA-4) — Phase 2 Topline Data in metastatic pancreatic cancer
Date: Q1 2026 (Est.)
BSI: 7.15/10

Tumor Treating Fields are wearable devices that deliver alternating electric fields to disrupt cancer cell division — a biophysical modality that recently won FDA approval for locally advanced pancreatic cancer based on survival data.

The Setup: NovoCure just got the locally advanced pancreatic cancer approval (Optune Pax from PANOVA-3) — the first new treatment modality for pancreatic cancer in over a decade. Now PANOVA-4 asks the harder question: does it work in metastatic disease, where nothing has moved the survival needle past Abraxane/gemcitabine? Six years of cash runway means this is an expansion play, not a survival trade. But the Phase 2 is small and the trial design drew skepticism about statistical powering.

Science & Edge: TTFields apply low-intensity alternating electric fields that disrupt mitosis in rapidly dividing cancer cells while sparing normal tissue. PANOVA-3 Phase 3 demonstrated survival benefit with Optune Pax plus gemcitabine/nab-paclitaxel versus chemo alone in locally advanced pancreatic cancer. The mechanism complements rather than competes with immunotherapy and chemotherapy, creating combination potential across tumor types.

The Edge: NovoCure already has three FDA-approved indications (GBM, mesothelioma/NSCLC, locally advanced pancreatic) proving the platform works in hard-to-treat cancers. Optune Pax's recent approval gives credibility to PANOVA-4. No direct competitor exists in biophysical cancer therapy — this is a category of one.
The Risk: PANOVA-4 is Phase 2 in metastatic disease. The trial design scored low on statistical rigor — small sample size and uncertain powering for a meaningful survival signal. Positive results would be directional, not registrational. Commercial uptake of TTFields has historically been slow due to physician skepticism, patient compliance with daily wear, and reimbursement friction.

#10. OSTX — OS Therapies Incorporated

THE CATALYST
Event: OST-HER2 (AOST-2121) — BLA Submission Data in resected osteosarcoma
Date: Q1 2026 (Est.)
FDA Status: Fast Track, Orphan Drug, RMAT Designation
BSI: 7.02/10

OST-HER2 targets HER2 expression in osteosarcoma — a pediatric bone cancer where the standard of care (cisplatin, doxorubicin, methotrexate) hasn't changed meaningfully in 30 years and 5-year survival remains below 70%.

The Setup: Three FDA designations (Fast Track, Orphan, RMAT) for a disease that affects ~400 kids per year in the US. No targeted therapy has ever been approved for osteosarcoma. OS Therapies initiated the BLA filing in February 2025, and the Type D meeting with FDA this month determines whether the data package is sufficient. Triple-designated, first-mover, zero competition in the indication — but $831K in cash and zero revenue. The company needs this regulatory meeting to go well to have any chance of financing through approval.

Science & Edge: OST-HER2 is a HER2-targeted immunotherapy for resected osteosarcoma, supported by Phase 2 data demonstrating clinical benefit in a population with no targeted options. HER2 overexpression in osteosarcoma is well-documented but no approved therapy exploits it. RMAT designation signals FDA sees potential for meaningful benefit over existing therapy — the strongest regulatory incentive available for regenerative/advanced therapies.

The Edge: Three simultaneous FDA designations — Fast Track, Orphan, RMAT — in an indication with no targeted therapy. Pediatric oncology commands premium pricing and orphan exclusivity locks out competition for seven years. The regulatory path is the most favorable possible for a rare disease BLA.
The Risk: $831K cash. That's not runway, that's fumes. The BLA process isn't free, and the Type D meeting is a checkpoint, not an approval. If FDA wants additional data, there's no money to generate it. Osteosarcoma's ~400 annual US cases create a real revenue ceiling even in the best case — this may need a partner to ever reach patients.

Watchlist

#11. MBRX — Moleculin Biotech Inc. [Oncology]

Price: $2.05 | Cap: $10.11M | Cash: $41.1K | RSI: 33.3 | Momentum: -51.0%
Annamycin — Phase 1/2 Full Results in acute myeloid leukemia (Q1 2026 Est.)
BSI: 7.76/10

The Intel: Annamycin is a next-gen anthracycline engineered to bypass multidrug resistance and eliminate the cardiotoxicity that forces oncologists to cap doxorubicin dosing. Phase 1/2 met its primary safety endpoint with zero cardiac events. The MIRACLE Phase 3 in relapsed/refractory AML is the goal, but $41K in cash and a micro float make this the purest binary in the scanner. Positive data is a lifeline; anything else is lights out.

#12. ALZN — Alzamend Neuro Inc. [Neurology]

Price: $2.09 | Cap: $7.95M | Cash: $1.92M | RSI: 57.1 | Momentum: +17.4%
AL001 — Phase 2 Topline Data in healthy subjects (Q1 2026 Est.)
BSI: 7.14/10

The Intel: AL001 is an ionic cocrystal reformulation of lithium designed for better tolerability in Alzheimer's, bipolar, and PTSD. Preclinical data showed cognitive and irritability benefits over lithium carbonate, but Phase 2 is in healthy volunteers — this readout establishes PK and safety, not efficacy. Cash crunch ($1.9M) and micro float amplify any news in either direction, but the catalyst itself is incremental.

#13. BCYC — Bicycle Therapeutics plc [Oncology]

Price: $5.04 | Cap: $349.61M | Cash: $518.61M | RSI: 41.1 | Momentum: -9.0%
Zelenectide pevedotin (BT8009) — Phase 1/2 End of Phase Meeting in solid tumors (Q1 2026 Est.)
FDA Status: Fast Track Designation
BSI: 6.96/10

The Intel: The market prices Bicycle's pipeline at negative — $519M cash versus a $350M market cap. BT8009's 60% ORR (SABCS) and 45% ORR (ESMO) with 11.1-month duration of response in nectin-4 tumors puts it in the conversation with Padcev (enfortumab vedotin), but using a synthetic peptide small enough to penetrate tumors that antibodies struggle to reach. Q1 regulatory feedback determines the pivotal path. Negative EV with Fast Track is an unusual combination.

#14. CLNN — Clene Inc. [Neurology]

Price: $5.92 | Cap: $64.23M | Cash: $28.65M | RSI: 73.4 | Momentum: +43.3%
CNM-Au8 (HEALEY ALS) — Phase 2/3 End of Phase Meeting in ALS (Q1 2026 Est.)
BSI: 6.91/10

The Intel: Gold nanocrystals for ALS sounds exotic, but the HEALEY platform trial survival data is real: 951-day median survival in the 30mg arm versus 753 days in the comparator — a 198-day gain. The Type C meeting with FDA this quarter determines whether that's enough for a Phase 3 path. Overbought at RSI 73 after a 43% run, with the market clearly positioning ahead of regulatory feedback. ALS drug development has a brutal track record of promising signals that don't replicate.

#15. KYTX — Kyverna Therapeutics Inc. [Immunology]

Price: $8.77 | Cap: $501.01M | Cash: $192.20M | RSI: 62.0 | Momentum: +16.2%
Miv-cel (KYV-101) — Phase 2 Interim Data in myasthenia gravis (Apr 20, 2026)
FDA Status: Fast Track, Orphan Drug, RMAT Designation
Additional catalysts: 1 more within 90 days (SPS data at AAN Apr 21)
BSI: 6.86/10

The Intel: Kyverna is pioneering CAR-T beyond oncology into autoimmune disease. Miv-cel showed 100% clinically meaningful responses in MG at 24 weeks (MG-ADL and QMG co-primaries both hit), and the SPS trial achieved all primary and secondary endpoints. Back-to-back AAN presentations on April 20-21 make this a double-catalyst week. BLA submission planned H1 2026 for SPS. The autoimmune CAR-T space is heating up after Cabaletta's and Equillium's moves, but Kyverna has the most advanced dataset in MG.

#16. INSM — Insmed Incorporated [Pulmonary]

Price: $139.52 | Cap: $30.07B | Cash: $1.23B | RSI: 20.5 | Momentum: -6.0%
ARIKAYCE (ENCORE) — Phase 3 Topline Data in MAC lung disease (Q1 2026 Est.)
BSI: 6.84/10

The Intel: Insmed is the largest company in the scanner by market cap — and the most oversold at RSI 20.5. ARIKAYCE is already approved for refractory MAC lung disease; ENCORE extends it to newly diagnosed and recurrent patients, which would roughly triple the addressable population. Phase 3 topline due imminently. This is a label expansion trade on an already-commercial asset with $1.2B cash, not a survival binary. The oversold condition suggests the market is nervous about execution, not viability.

#17. IDYA — IDEAYA Biosciences Inc. [Oncology]

Price: $32.83 | Cap: $2.88B | Cash: $567.00M | RSI: 54.5 | Momentum: +2.9%
Darovasertib + crizotinib (OptimUM-02) — Phase 2/3 Topline Data in metastatic uveal melanoma (Q1 2026 Est.)
BSI: 6.68/10

The Intel: Uveal melanoma has almost nothing — tebentafusp is approved but restricted to HLA-A02-positive patients (~50%). Darovasertib targets GNAQ/11 mutations (present in ~90% of uveal melanoma) via PKC inhibition, combined with crizotinib. OptimUM-02 enrolled HLA-A02-negative patients — the exact population tebentafusp can't reach. Enrollment completed December 2025, topline data expected last week of March. Well-funded with $567M cash and 18 months of runway.

#18. ORIC — Oric Pharmaceuticals Inc. [Oncology]

Price: $11.76 | Cap: $1.18B | Cash: $263.50M | RSI: 54.3 | Momentum: +15.3%
Rinzimetostat (ORIC-944) — Phase 1b Full Results in metastatic castration-resistant prostate cancer (Q1 2026 Est.)
BSI: 6.67/10

The Intel: Rinzimetostat is a glucocorticoid receptor antagonist designed to overcome resistance to androgen receptor inhibitors in mCRPC — a mechanism Oric believes is behind why enzalutamide and abiraterone eventually fail. Phase 1b showed 55% PSA50 response rate and 20% PSA90. Phase 3 planned for H1 2026. Three years of runway removes financing pressure. The question is whether dose optimization data this quarter is strong enough to set up the pivotal trial design.

#19. ACIU — AC Immune SA [Neurology]

Price: $3.00 | Cap: $301.23M | Cash: $36.28M | RSI: 71.4 | Momentum: -1.0%
ACI-15916 PET — Phase 1 Initial Data in Parkinson's disease (Q1 2026 Est.)
BSI: 6.59/10

The Intel: AC Immune is developing a PET imaging tracer for alpha-synuclein, the misfolded protein behind Parkinson's. An accurate synuclein PET would be transformative for drug development — every pharma company running synuclein-targeting trials needs a way to confirm target engagement. Phase 1 initial data this quarter is early-stage and diagnostic, not therapeutic. Note: our scoring flagged this on catalyst materiality and trial design — this is a Phase 1 imaging study, not a drug readout. Approach as a long-term platform story, not a near-term trade.

#20. OKYO — OKYO Pharma Limited [Ophthalmology]

Price: $1.70 | Cap: $57.53M | Cash: $6.33M | RSI: 50.0 | Momentum: -12.8%
Urcosimod (OK-101) — Phase 2a Conference Presentation for neuropathic corneal pain (Apr 11, 2026)
FDA Status: Fast Track Designation
BSI: 6.54/10

The Intel: Urcosimod is a chemerin receptor agonist targeting neuropathic corneal pain — an indication with no approved treatment and no competitor in clinical development. OKYO was the first company to get an IND specifically for NCP. Phase 2a data completed Q2 2025, with presentations at ASCRS (April 11) and ARVO (May 3-7). Note: our scoring flagged catalyst materiality as a concern — conference presentations are incremental catalysts, not binary events. Limited cash ($6.3M) adds financing risk.

The Strategist's Take

Three themes define this week's scanner. First, the PDUFA duo — RCKT (March 28) and GRCE (April 23) offer the cleanest binary setups. Both are orphan indications with no competition, both have met their pivotal endpoints, and both outcomes will be unambiguous. Rocket's prior CRL adds drama; Grace's niche ICU market adds ceiling questions. But for pure event-driven trades, these are the two.

Second, the Phase 3 cluster — KPTI, ALMS, and KOD all expect topline data within weeks. Karyopharm's SENTRY trial in myelofibrosis is the highest-conviction setup (BSI 7.02), targeting a space where the standard of care has clear limitations and no combination has won in a randomized Phase 3. Alumis faces a different kind of test — not whether ESK-001 works (Phase 2 says it does), but whether it works well enough to compete with biologic benchmarks that set a very high bar. Kodiak is the comeback story, hoping a reformulated drug can recapture a thesis the market nearly abandoned.

Third, the cash crisis names — PCSA, OSTX, and MBRX all have under $1M in cash. These aren't investments; they're lottery tickets. Positive data from any of them could move stock prices dramatically on micro floats, but the downside scenario in each case is existential. MBRX's high BSI score (7.76) reflects strong ML technicals and a clean Phase 1/2 safety dataset, but the zero-cash reality makes this appropriate for the watchlist, not the featured picks. Two watchlist candidates — ACIU and OKYO — were flagged by our scoring on catalyst materiality, meaning their upcoming events are incremental (a PET imaging study, a conference poster) rather than binary. Worth monitoring, but set expectations accordingly.

About This Scanner

This weekly report identifies biotech catalyst opportunities using quantitative screening combined with fundamental analysis.

What the Score Means: The BSI Score (0-10) reflects overall opportunity quality based on technical setup and fundamental characteristics. Higher scores indicate more favorable setups; lower scores indicate elevated uncertainty. This is NOT a prediction of catalyst outcomes or stock direction.

Data Sources: Financial data from market feeds and regulatory filings. Catalyst dates are estimates based on company guidance and subject to change.

Important: This report is for informational and educational purposes only. It does not constitute investment, financial, or medical advice. Conduct your own due diligence before making investment decisions.

Disclaimer

The information provided is for informational purposes only and should not be construed as financial, investment, legal, or professional advice.

Key Risks:

Clinical trials: Most drug candidates fail in development
Regulatory: FDA decisions remain unpredictable
Financing: Companies may dilute at any time
Volatility: Small-cap biotech stocks experience extreme price swings

Past performance does not guarantee future results.

Scanner Version: 3.0 | Generated: 2026-03-13